Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01021956 · ClinicalTrials.gov registry record · Phase 2
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
A Phase 2 study, sponsored by Steba Biotech S.A..
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01021956: Clinical Trial Phase 2 study, sponsored by Steba Biotech S.A..
NCT01021956 is a Phase 2 study that was terminated before completion, run by Steba Biotech S.A.. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01021956, a Phase 2 study, was terminated before completion, sponsored by Steba Biotech S.A..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti Vascular Endothelium Growth Factor (anti VEGF) intravitreal therapy in the first 12 weeks after VTP. All subjects will have a 52 weeks safety follow up telephone call (Not for Adverse Events (AEs) collection).
Primary Outcome
Adverse events (AEs) consisting in Eye disorders, related or non related were collected throughout the study.
Interventions
- DRUG STAKEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-06 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Why NCT01021956 stopped before completion
NCT01021956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which STAKEL is the first listed.
NCT01021956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01021956 about?
NCT01021956 is a clinical study titled "Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD". The objectives of this study are to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular Age related Macular Degeneration (AMD). The drug product is activated in patients by exposure to light at a specific wavelen...
What is the current status of trial NCT01021956?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-06. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01021956?
The interventions under investigation include: STAKEL (DRUG).
Who is sponsoring clinical trial NCT01021956?
This trial is sponsored by Steba Biotech S.A., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01021956's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia